Receptor basis for dopaminergic supersensitivity in Parkinson's disease

[1]  P. Seeman,et al.  Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. , 1977, Life sciences.

[2]  P. Seeman,et al.  Anti-schizophrenic drugs--membrane receptor sites of action. , 1977, Biochemical pharmacology.

[3]  J. Leysen,et al.  Differentiation of opiate and neuroleptic receptor binding in rat brain. , 1977, European journal of pharmacology.

[4]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[5]  I. Creese,et al.  Neurotransmitter receptor binding: regional distribution in human brain , 1977, Journal of neurochemistry.

[6]  J. Leysen,et al.  Blockade of apomorphine's discriminative stimulus properties: Relation to neuroleptic activity in neuropharmacological and biochemical assays , 1976, Pharmacology Biochemistry and Behavior.

[7]  P. Seeman,et al.  Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Davis,et al.  Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. , 1976, Life sciences.

[9]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[10]  I. Creese,et al.  The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. , 1975, Life sciences.

[11]  P. Seeman,et al.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Snyder,et al.  Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. , 1975, Life sciences.

[13]  O. Hornykiewicz.  Parkinson's disease and its chemotherapy. , 1975, Biochemical pharmacology.

[14]  R. Baldessarini,et al.  Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. , 1974, Neuropharmacology.

[15]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[16]  H. Klawans.  The pharmacology of tardive dyskinesias. , 1973, The American journal of psychiatry.

[17]  D. Sharman,et al.  The effect of tropolone on the formation of 3,4‐dihydroxyphenylacetic acid and 4‐hydroxy‐3‐methoxyphenylacetic acid in the brain of the mouse , 1969, British journal of pharmacology.

[18]  K. Taylor,et al.  The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique. , 1968, Analytical biochemistry.

[19]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[20]  J. Ajuriaguerra.  Monoamines et système nerveux central , 1962 .

[21]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.